Proactive news headlines: Oncimmune, Remote Monitored Systems, Record, Bidstack Group...
A glance at some of the day's highlights from the Proactive Investors newswire
Company
Oncimmune Holdings PLC
LON:ONC
Oncimmune Holdings PLC is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The company has a diversified and growing revenue from its portfolio of diagnostic products to detect early-stage cancer and a contract discovery and development service-based platform, delivering actionable insights into therapies to its pharmaceutical and biotech partners.
139 stories · page 3 of 7
Oncimmune signs deal with world-renowned Dana-Farber Cancer Institute
The firm's SeroTag technology will be used to assess for resistance to checkpoint inhibitor drugs and chemotherapy
Oncimmune technology used by Cedars-Sinai researchers in breakthrough COVID-19 research
The team found the virus affects men and women differently, which could have an impact on the way second and third-generation vaccines are developed
Oncimmune looking to ImmunoINSIGHTS to deliver another step-change in revenue growth
If things go as expected, the first quarter of the current fiscal year should see the company secure roughly half the revenues the market expects for the whole year
Proactive news headlines: MBH Corporation, Oncimmune, Eckoh, Coinsilium Group...
A glance at some of the day's highlights from the Proactive Investors newswire
Oncimmune strikes deal with partner to take back China and Hong Kong rights to its technology
The company said the agreement with Genostics would also allow it to “pursue the optimum route to market in this important territory"
Archive
Proactive news headlines: Oncimmune, Alien Metals, Cornerstone FS, Gore Street Energy Storage...
A glance at some of the day's highlights from the Proactive Investors newswire
Oncimmune Holdings wins COVID-19 contracts with Roche and Cedars-Sinai Medical Center
They will use an infectious disease panel that can help predict the severity of COVID-19 along with the potential effectiveness of vaccines and other drugs used to treat it
Oncimmune raises £9mln to expand ImmunoINSIGHTS business
Proceeds will fund the biotech services business to expand amid high commercial demand, to double capacity this year, and, double it again next year.
Oncimmune Holdings sees sixfold increase in half-year revenues
ImmunoINSIGHTS commercial activity has been strong, with seven contracts signed since the beginning of June.
Oncimmune delivering top-line growth
Oncimmune is a specialist in the field of immunodiagnostics
Oncimmune says Dr Cheung To, of significant shareholder Genostics, has stepped down as a non-executive director
Genostics remains Oncimmune's exclusive partner in China and continues to work closely with Oncimmune to gain market entry
Oncimmune says team plays important role in helping define a new approach to rheumatoid arthritis
Researchers from the ImmunoINSIGHTS operation worked alongside scientists from Roche and University Medical Center Utrecht
Oncimmune higher as it sees commercial traction for lung blood test; successful NICE assessment would support wider adoption
The group has landed two early commercial deals, while its technology is being formally looked at by the National Institute for Health and Care Excellence (NICE)
Oncimmune Holdings signs master service agreement with California-based immunotherapy specialist
It will profile patient plasma samples and assess treatment candidates discovered using the Augmenta's SingleCyte and DeepGrid platforms
Oncimmune Holdings generating a growing pipeline of opportunities
Chief executive Adam Hill said he expects the business to generate "substantial further growth"
Oncimmune says lung blood test part of a clinical study assessing the screening potential of the technology
“Oncimmune is committed to producing further evidence that supports both adoption and reimbursement decisions in the markets where EarlyCDT Lung is available,” said chief executive Adam Hill
Oncimmune welcomes independent validation of its lung blood test
The data were presented in detail at the recent American College of Chest Physicians (CHEST) annual meeting
Archive
Proactive news headlines: Oncimmune, BlueRock Diamonds, Ncondezi Energy, Capital Limited …
A glance at some of the day's highlights from the Proactive Investors newswire
Oncimmune links up with world-renowned Cedars-Sinai for COVID-19 programme
“We expect to announce further development collaborations and contracts over the coming months to be followed by contracts with biopharmaceutical companies once the COVID-19 panel is fully validated," said chief executive, Adam Hill